Go to contentGo to menuGo to searchGo to the news list

MitoVasc : physiopathologie cardiovasculaire et mitochondriale

Main navigation





    • Share this page on social networks
    • E-mail this page

      Send by mail

      Separated by coma
    • Print this page

    Mitochondrial medicine, a challenge for tomorrow

    Angers University welcomes the pioneer in mitochondrial medicine

    2nd December 2015

    The Mitochondrial Medicine Research Centre (MMRC/PREMMi) is honored to organize the symposium:« Mitochondrial medicine, a challenge for tomorrow »on December 2nd, 2015.



    Mitochondrial medicine, a challenge for tomorrow

    Chairman: Professor Douglas Wallace

    • Mitochondrial medicine in the 21st century – Prof. Douglas Wallace (Philadelphia USA)
    • How can plant studies contribute to mitochondrial medicine? – Prof. André Dietrich (Strasbourg, France)
    • Mitochondrial dynamics and energy metabolism in metabolic diseases – Prof. Antonio Zorzano (Barcelona, Spain)
    • Genetic landscape of Leber's hereditary optic neuropathy: reflections on pathogenic mechanisms – Prof. Valerio Carelli (Bologna, Italy)

    Practical information:  

    Wednesday, December 2nd, 2015 from 9 am to 12:30 am. UFR Santé (Université d’Angers) – Room: Amphi 200 (Rue Haute de Reculée – Angers, France)

    Registration(free but compulsory): secretariat.premmi@univ-angers.fr


    About the speakers:

    Professor Douglas Wallace from Pennsylvania University (Philadelphia, USA) has performed major discoveries in mitochondrial genetics. Member of the US Academy of Arts and Sciences and the National Academy of Sciences, he has authored over 450 publications while working in the most important US Universities such as Yale, Stanford, Emory, Irvine and Pennsylvania. Currently he is managing the Center of Mitochondrial and Epigenomics Medicine at the Children Hospital in Philadelphia. He will present the perspectives of Mitochondrial Medicine in the 21st century.

    Professor André Dietrich is Research Director at the CNRS in the Institute for Plants Molecular Biology of Strasbourg University (France). His research domain deals with the regulation and inverse genetics of plants mitochondria. His work aims at identifying mitochondrial mechanisms of genetic expression coordination, genome integrity maintenance and their role in mitochondrial physiology.

    Professor Antonio Zorzano is professor in molecular biology and biochemistry and research director at the Institute for Research in Biomedicine of Barcelona (Spain). His research activity focuses on the elucidation of molecular mechanisms involving mitochondria in the development of insulin resistance, obesity and type 2 diabetes.

    Professor Valerio Carelli is professor in neurology and director of the research laboratory in Neurogenetics of the University of Bologna (Italy) and Associate professor in ophthalmology at the Doheny Eye Institute of Los Angeles (USA), his research is centered on the key role of mitochondrial alterations in neuro-ophthalmological diseases.


    About PREMMi

    The Mitochondrial Medicine Research Centre (MMRC/PREMMi), based in Angers and headed by Guy Lenaers (DR CNRS) gathers all the local laboratories involved in mitochondria investigations, hence creating a scientific dynamics for the emergence of a unique, international-sized, mitochondrial medicine consortium.

    The MMRC/PREMMi strategy consists in transferring the knowledge and skills acquired on mitochondrial hereditary rare diseases to common diseases involving mitochondrial dysfunction (Alzheimer, Parkinson, cancer, diabetes, cardio-vascular diseases, aging).

    Currently, there are only two structures of this type worldwide, among which the "Center for Mitochondrial and Epigenomic Medicine » headed by Pr. Douglas Wallace in Philadelphia (USA); in which Prof. Vincent Procaccio, member of PREMMi actively contributed.

    One of the main challenges in mitochondrial medicine is to identify therapeutic pathways targeting mitochondria in many diseases for which there is no treatment yet available.

    The MMRC/PREMMi program favors the reinforcement of collaborations between plant and metazoan life sciences research axes. From this alliance, new therapeutic molecules should be identified to generating tomorrow’s medicine for common diseases with a mitochondrial deficit.